Compounded Semaglutide vs Ozempic vs Wegovy: What's Actually Different?

Ozempic became a cultural phenomenon. Wegovy followed. Then compounded semaglutide arrived — same active ingredient, a fraction of the price — and suddenly millions of people who couldn't afford or access branded GLP-1 had an option.

If you're trying to understand whether compounded semaglutide is legitimate, safe, and worth it, here's the clear-eyed answer.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. The same molecule is sold as: - Ozempic — FDA-approved for type 2 diabetes (0.5mg, 1mg, 2mg weekly injections) - Wegovy — FDA-approved for chronic weight management (up to 2.4mg weekly) - Rybelsus — oral semaglutide for diabetes

The same compound. Different FDA approvals, different dosing, different pricing.

What Is Compounded Semaglutide?

Compounding is the process of creating customized medications from bulk pharmaceutical ingredients (active pharmaceutical ingredients, or API). It's been around for decades — compounding pharmacies make medications that: - Aren't commercially available in the needed dose or form - Are on FDA shortage lists - Require patient-specific modifications

Compounded semaglutide uses semaglutide API (pharmaceutical-grade semaglutide) combined with other ingredients to create an injectable solution that functions identically to Ozempic/Wegovy from a pharmacology standpoint.

Key distinction: Compounded drugs are not FDA-approved as finished products. They are, however, legal when produced by licensed pharmacies for patient-specific prescriptions.

Is the Active Ingredient Actually the Same?

Yes. Pharmaceutical-grade semaglutide API — used by legitimate compounding pharmacies — is the same molecule as what's in Ozempic. The key word is "pharmaceutical-grade" — meeting USP (United States Pharmacopeia) standards for purity and identity.

The debate around "semaglutide salt" vs "semaglutide base" has circulated in this space. Some compounding pharmacies use semaglutide sodium or acetate salt forms. The clinical significance of this is disputed — the active molecule is the same, though theoretical differences in bioavailability exist. Reputable compounding pharmacies and the FDA have weighed in; the legitimate API form is semaglutide free base or its pharmaceutical salt forms with equivalent activity.

What to avoid: sketchy online vendors selling "research peptides" or "semaglutide powder" for self-compounding. That's a different category entirely from licensed pharmacy compounding.

The Regulatory Landscape

Understanding why compounded semaglutide became so widespread requires understanding the FDA shortage framework.

When branded semaglutide (Ozempic/Wegovy) entered the FDA shortage list in 2022-2023, compounding pharmacies gained explicit permission to compound the molecule — shortage medications can be compounded without the usual restrictions.

In early 2025, the FDA declared Wegovy off the shortage list. This created legal uncertainty for ongoing compounding. The situation as of 2026 is nuanced: compounding pharmacies that can demonstrate patient-specific medical necessity or produce for patients who have had adverse reactions to branded products can continue. Telehealth platforms navigate this on behalf of their patients.

The bottom line on regulatory status: Compounded semaglutide from licensed pharmacies is legal today. The pathway requires physician prescription and patient-specific justification. Platforms like Marrow handle this compliance layer.

Quality Differences: What Actually Matters

Brand name (Ozempic/Wegovy): - FDA-approved finished drug product - Manufactured in FDA-inspected facilities with extensive quality controls - Novo Nordisk auto-injector pen (user-friendly, accurate dosing) - Cold-chain shipping and storage standards rigorously enforced

Compounded semaglutide (from reputable source): - Not FDA-approved as a finished product - Quality depends on pharmacy — 503B outsourcing facilities (FDA-registered) have substantially higher standards than 503A compounding pharmacies - Vial + syringes (less polished than branded pen, but functional) - Cold-chain shipping still required and should be confirmed

What this means in practice: Compounded semaglutide from a reputable 503B facility is manufactured with pharmaceutical-grade quality controls. It's not the same as a Novo Nordisk approved facility, but it's not "sketchy pills from the internet" either. The difference in real-world efficacy for most patients is indistinguishable.

The risk of compounded semaglutide is almost entirely sourcing-related — buying from unlicensed sources, telehealth mills that aren't verifying pharmacy quality, or products that contain different compounds than labeled. A reputable platform vets their compounding partner rigorously.

The Price Reality

This is where the comparison becomes stark:

| Product | Price (monthly) | Insurance coverage | |---------|----------------|-------------------| | Ozempic (1mg) | $800-1,000 | Often requires diabetes Dx | | Wegovy (2.4mg) | $1,100-1,300 | Limited, prior auth required | | Compounded semaglutide | $199-299 | No — but doesn't need it |

The 70-80% cost reduction from branded to compounded is the story of why this market exists. When the same molecule achieves the same clinical result at a fraction of the price, the value case is strong.

Clinical Outcomes Comparison

No head-to-head RCTs compare compounded vs branded semaglutide with sufficient statistical power — the regulatory status makes such trials unlikely. But:

• The mechanism is identical (same molecule, same receptor target)
• Real-world outcomes reported across telehealth platforms are consistent with SUSTAIN/STEP trial data for branded semaglutide
• Weight loss of 12-18% over 52 weeks is achievable with either at therapeutic doses

The difference in outcomes is not pharmacological — it's adherence. Patients who can afford their medication long-term achieve better outcomes. Compounded semaglutide at $249/month has dramatically higher long-term adherence than branded at $1,000+/month.

Who Should Use Branded vs Compounded?

Consider branded if: - You have insurance coverage that makes branded cost-competitive - You have documented adverse reactions to the compounded formulation - You want the highest-confidence regulated product regardless of cost - You're a type 2 diabetic with cardiovascular disease (Ozempic's CV outcome data is specifically for the branded product)

Compounded makes sense if: - You're paying out-of-pocket and the cost difference is meaningful - You're using it for weight loss/optimization rather than specifically for diabetes - You're working with a reputable telehealth platform that vets pharmacy quality

The Bottom Line

Compounded semaglutide from a reputable, licensed pharmacy is pharmacologically equivalent to Ozempic/Wegovy, substantially less expensive, and legally accessible through physician-supervised telehealth. The caveats are about sourcing — use a platform that is transparent about their compounding pharmacy partners and can document 503B facility status.

The brand premium for Ozempic exists. Whether it's worth $750/month more is a personal calculation.

[Get compounded semaglutide at Marrow](/start) — $249/month, physician-supervised.